Current strategies in the management of hypereosinophilic syndrome, including mepolizumab

Current Medical Research and Opinion

Volumn 26, Issue 8, 2010, Pages 1933-1946

  Schwartz, Lawrence B ^a   Sheikh, Javed ^b   Singh, Anish ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Empire Clinic   (Australia)

Author keywords

Corticosteroids; Hypereosinophilic syndrome; Mepolizumab; Side effects

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; CORTICOSTEROID; FIP1 LIKE 1 PLATELET DERIVED GROWTH FACTOR ALPHA; HYBRID PROTEIN; HYDROXYUREA; IMATINIB; INFLIXIMAB; INTERLEUKIN 5; MEPOLIZUMAB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RESLIZUMAB; SUPLATAST TOSYLATE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALTERNATIVE MEDICINE; ARTHRALGIA; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORTICOSTEROID THERAPY; CYTOPENIA; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; EDEMA; ENDOCRINE DISEASE; EOSINOPHILIA; EYE DISEASE; FATIGUE; FLU LIKE SYNDROME; FLUID RETENTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GENE FUSION; GENE MUTATION; GENE OVEREXPRESSION; HEPATOBILIARY DISEASE; HUMAN; HYPEREOSINOPHILIC SYNDROME; HYPERTRANSAMINASEMIA; IMMUNOMODULATION; IMMUNOPATHOLOGY; METABOLIC DISORDER; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; QUALITY OF LIFE; RASH; SHORT SURVEY; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADRENAL CORTEX HORMONES; AGED; ANTIBODIES, MONOCLONAL; HUMANS; HYPEREOSINOPHILIC SYNDROME; INTERLEUKIN-5; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 77954752964     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.493132     Document Type: Short Survey

References (102)

1. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994;83:2759-79
2. Chusid MJ, Dale DC, West BC, et al. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975;54:1-27
3. Klion AD. Approach to the therapy of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007;27:551-60
4. Sheikh J, Weller PF. Clinical overview of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007;27:333-55
5. Klion A. Hypereosinophilic syndrome: current approach to diagnosis and treatment. Annu Rev Med 2009;60:293-306
6. Cogan E, Schandene L, Crusiaux A, et al. Brief report: clonal proliferation of type 2 helper T-cells in a man with the hypereosinophilic syndrome. N Engl J Med 1994;330:535-8
7. + T-cell population able to secrete large amounts of interleukin-5. Blood 1996;87:1416-22
8. Simon HU, Yousefi S, Dommann-Scherrer CC, et al. Expansion of cytokine-producing CD4~CD8~ T-cells associated with abnormal Fas expression and hypereosinophilia. J Exp Med 1996;183:1071-82
9. Simon HU, Plötz SG, Dummer R, et al. Abnormal clones of T-cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999;341:1112-20
10. Roufosse F, Schandene L, Sibille C, et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol 2000; 109:540-8
11. +CD3~ helper type 2 (Th2) lymphocytes. Leuk Lymphoma 2001;42:123-33
12. Roufosse F, Cogan E, Goldman M. Lymphocytic variant hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007;27:389-413
13. de Lavareille A, Roufosse F, Schmid-Grendelmeier P, et al. High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome. J Allergy Clin Immunol 2002;110:476-9
14. Roufosse F, Cogan E, Goldman M. Recent advances in pathogenesis and management of hypereosinophilic syndromes. Allergy 2004;59:673-89
15. Flaum MA, SchooleyRT, Fauci AS, etal. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. I. Hematologic manifestations. Blood 1981;58:1012-20
16. Schooley RT, Flaum MA, Gralnick HR, et al. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations. Blood 1981;58:1021-6
17. Bain BJ, Fletcher SH. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol Allergy Clin North Am 2007;27:377-88
18. Cools J, DeAngeloDJ, GotlibJ, etal. Atyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-14
19. Klion AD. Recent advances in the diagnosis and treatment of hypereosinophilic syndromes. Hematology 2005;2005:209-14
20. Klion AD, Bochner BS, Gleich GJ, et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 2006;117:1292-302
21. Gleich GJ, Leiferman KM. The hypereosinophilic syndromes: still more heterogeneity. Curr Opin Immunol 2005;17:679-84
22. Roufosse F, Goldman M, Cogan E. Hypereosinophilic syndrome: lymphopro-liferative and myeloproliferative variants. Semin Respir Crit Care Med 2006; 27:158-70
23. Klion AD, Law MA, Riemenschneider W, et al. Familial eosinophilia: a benign disorder? Blood 2004;103:4050-5
24. Gleich GJ, Schroeter AL, Marcoux JP, et al. Episodic angioedema associated with eosinophilia. N Engl J Med 1984;310:1621-6
25. Benvenisti DS, Ultmann JE. Eosinophilic leukemia. Report of five cases and review of literature. Ann Intern Med 1969;71:731-45
26. Roberts WC, Liegler DG, Carbone PP. Endomyocardial disease and eosinophilia. A clinical and pathologic spectrum. Am J Med 1969;46:28-42
27. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol 2006; 24:147-74
28. Wilkins HJ, Crane MM, Copeland K, et al. Hypereosinophilic syndrome: an update. Am J Hematol 2005;80:148-57
29. Fauci AS, Harley JB, Roberts WC, et al. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 1982;97:78-92
30. Shah R, Ananthasubramaniam K. Evaluation of cardiac involvement in hypereosinophilic syndrome: complementary roles of transthoracic, transesophageal, and contrast echocardiography. Echocardiography 2006;23:689-91
31. Roufosse F, Cogan E, Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med 2003;54:169-84
32. Vaklavas C, Tefferi A, Butterfield J, et al. 'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course. Leuk Res 2007;31:691-4
33. Vandenberghe P, Wlodarska I, Michaux L, et al. Clinical and molecular features of FIP1L1-PDGFRA (+) chronic eosinophilic leukemias. Leukemia 2004;18:734-42
34. Klion AD, Noel P, Akin C, etal. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003;101:4660-6
35. von Bubnoff N, Sandherr M, Schlimok G, et al. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 2005; 19:286-7
36. Kalac M, Quintas-Cardama A, Vrhovac R, et al. A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. Cancer 2007;110:955-64
37. Bush RK, Geller M, Busse WW, et al. Response to corticosteroids in the hypereosinophilic syndrome. Association with increased serum IgE levels. Arch Intern Med 1978;138:1244-6
38. Miyazawa K, Kakazu N, Ohyashiki K. Clinical features of hypereosinophilic syndrome: FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid. Int J Hematol 2007;85:5-10
39. Novartis. Gleevec® (imatinib mesylate) tablets United States prescribing information. Available at http://www.pharma.us.novartis.com/product/ pi/pdf/gleevec-tabs.pdf. Accessed 15 Jan, 2008
40. Prin L, Lefebvre P, Gruart V, et al. Heterogeneity of human eosinophil glucocorticoid receptor expression in hypereosinophilic patients: absence of detectable receptor correlates with resistance to corticotherapy. Clin Exp Immunol 1989;78:383-9
41. Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med 1978;89:167-72
42. Butterfield JH. Treatment of hypereosinophilic syndromes with prednisone, hydroxyurea, and interferon. Immunol Allergy Clin North Am 2007;27: 493-518
43. Butterfield JH. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol 2005;114:26-40
44. Simon HU, Cools J. Novel approaches to therapy of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007;27:519-27
45. Schandene L, Roufosse F, de Lavareille A, et al. Interferon a prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosino-philia. Blood 2000;96:4285-92
46. Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol 2006;148:245-54
47. Cole TJ. Glucocorticoid action and the development of selective glucocorticoid receptor ligands. Biotechnol Annu Rev 2006;12:269-300
48. Schacke H, Berger M, Rehwinkel H, et al. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 2007;275:109-17
49. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23-43
50. Klion AD, Weller PF. Idiopathic and other hypereosinophilic syndromes. uptodate.com 2006:1-15
51. Butterfield JH, Ackerman SJ, Weiler D, et al. Effects of glucocorticoids on eosinophil colony growth. J Allergy Clin Immunol 1986;78:450-7
52. Her E, Frazer J, Austen KF, et al. Eosinophil hematopoietins antagonize the programmed cell death of eosinophils. Cytokine and glucocorticoid effects on eosinophils maintained by endothelial cell-conditioned medium. J Clin Invest 1991;88:1982-7
53. Lamas AM, Leon OG, Schleimer RP. Glucocorticoids inhibit eosinophil responses to granulocyte-macrophage colony-stimulating factor. J Immunol 1991;147:254-9
54. Hallsworth MP, Litchfield TM, Lee TH. Glucocorticoids inhibit granulocyte-macrophage colony-stimulating factor-1 and interleukin-5 enhanced in vitro survival of human eosinophils. Immunology 1992;75:382-5
55. Wallen N, Kita H, Weiler D, et al. Glucocorticoids inhibit cytokine-mediated eosinophil survival. J Immunol 1991;147:3490-5
56. Sabag N, Castrillon MA, Tchernitchin A. Cortisol-induced migration of eosinophil leukocytes to lymphoid organs. Experientia 1978;34:666-7
57. Woodworth BA, Joseph K, Kaplan AP, et al. Alterations in eotaxin, monocyte chemoattractant protein-4, interleukin-5, and interleukin-13 after systemic steroid treatment for nasal polyps. Otolaryngol Head Neck Surg 2004;131:585-9
58. Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol 2001;33:289-94
59. Stanbury RM, Graham EM. Systemic corticosteroid therapy-side effects and their management. Br J Ophthalmol 1998;82:704-8
60. Schoepe S, Schacke H, May E, et al. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol 2006;15:406-20
61. Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol 2000;16:505-11
62. Canalis E, Mazziotti G, GiustinaA, etal. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007;18:1319-28
63. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc 2006;81:1361-7
64. Renfro L, Snow JS. Ocular effects of topical and systemic steroids. Dermatol Clin 1992;10:505-12
65. Wolfe F, Hawley DJ. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients. J Rheumatol 2000;27: 1668-73
66. Macdonald D, Cross NC. Chronic myeloproliferative disorders: the role of tyrosine kinases in pathogenesis, diagnosis and therapy. Pathobiology 2007;74:81-8
67. Wadleigh M, DeAngelo DJ, Griffin JD, et al. After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. Blood 2005;105:22-30
68. Gleich GJ, Leiferman KM, Pardanani A, et al. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002;359:1577-8
69. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003;102:3093-6
70. Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004;104:3038-45
71. Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004; 103:473-8
72. Muller AM, Martens UM, Hofmann SC, et al. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature. Ann Hematol 2006;85:1-16
73. Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with FIP1/1-PDGFRa-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007; 92:1173-9
74. Hensley ML, Ford JM. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol 2003;40:21-5
75. Atallah E, Kantarjian H, Cortes J. Emerging safety issues with imatinib and other abl tyrosine kinase inhibitors. Clin Lymphoma Myeloma 2007;7 (Suppl 3):S105-12
76. Pardanani A, Reeder T, Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003;101:3391-7
77. Arai A, Yan W, Wakabayashi S, et al. Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity. Int J Hematol 2007;86:233-7
78. La Starza R, Specchia G, Cuneo A, et al. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases. Haematologica 2005; 90:596-601
79. De Keersmaecker K, Cools J. Chronic myeloproliferative disorders: a tyrosine kinase tale. Leukemia 2006;20:200-5
80. Owen WF, Rothenberg ME, Petersen J, et al. Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome. J Exp Med 1989;170:343-8
81. Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood 1992;79: 3101-9
82. Koury MJ, Newman JH, Murray JJ. Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib. Am J Med 2003;115:587-9
83. Plotz SG, Simon H-U, Darsow U, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003;349:2334-9
84. Garrett JK, Jameson SC, Thomson B, et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 2004; 113:115-19
85. Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008;358: 1215-28
86. Quintas-Cardama A, Tefferi A, Cortes J, et al. Alemtuzumab (CAMPATH-1HTM) is effective therapy for hypereosinophilic syndrome (HES). Blood 2006;108:ASH Annual Meeting abstracts [Abstract 4902]
87. Pitini V, Teti D, Arrigo C, et al. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T-cells: a case report. Br J Haematol 2004;127:477
88. Sefcick A, Sowter D, DasGupta E, et al. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol 2004;124:558-9
89. Taverna JA, Lerner A, Goldberg L, et al. Infliximab as a therapy for idiopathic hypereosinophilic syndrome. Arch Dermatol 2007;143:1110-12
90. Walsh GM. Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions. Curr Opin Mol Ther 2009; 11:329-36
91. Yamada Y, Yoshihara S, Arisaka O. Successful treatment of pediatric hyper-eosinophilic syndrome with suplatast tosilate. Ann Allergy Asthma Immunol 2007;99:380-1
92. Hart TK, Cook RM, Zia-Amirhosseini P, et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol 2001;108:250-7
93. Gnanakumaran G, Babu KS. Technology evaluation: mepolizumab, GlaxoSmithKline. Curr Opin Mol Ther 2003;5:321-5
94. Sutton SA, Assa'ad AH, Rothenberg ME. Anti-IL-5 and hypereosinophilic syndromes. Clin Immunol 2005;115:51-60
95. Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009;124:1319-25.e3
96. European Medicines Agency. Press release: GlaxoSmithKline withdraws its marketing authorisation application for Bosatria (mepolizumab). Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/bosatria/48376009en.pdf. European Medicines Agency, 29 July 2009
97. Williams LC, Nesbitt Jr LT, Update on systemic glucocorticosteroids in dermatology. Dermatol Clin 2001;19:63-77
98. Recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 2001;44:1496-503
99. Liu RH, Werth VP. What is new in the treatment of steroid-induced osteoporosis? Semin Cutan Med Surg 2006;25:72-8
100. Shibli-Rahhal A, Van Beek M, Schlechte JA. Cushing's syndrome. Clin Dermatol 2006;24:260-5
101. Brown ES, Chandler PA. Mood and cognitive changes during systemic corticosteroid therapy. Prim Care Companion J Clin Psychiatry 2001; 3:17-21
102. Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007;66:1560-7